Short Interest in Portage Biotech Inc. (NASDAQ:PRTG) Expands By 33.8%

Portage Biotech Inc. (NASDAQ:PRTG) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 17,400 shares, a growth of 33.8% from the February 13th total of 13,000 shares. Based on an average trading volume of 650,300 shares, the short-interest ratio is currently 0.0 days. Approximately 10.6% of the company’s stock are short sold.

Hedge Funds Weigh In On Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Virtu Financial LLC acquired a new position in Portage Biotech Inc. (NASDAQ:PRTG) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned 1.04% of Portage Biotech at the end of the most recent reporting period. 13.36% of the stock is owned by institutional investors.

Portage Biotech Trading Up 1.2 %

NASDAQ PRTG traded up $0.05 during trading hours on Tuesday, reaching $4.30. 3,221 shares of the company traded hands, compared to its average volume of 641,543. The stock has a market capitalization of $4.51 million, a PE ratio of -0.10 and a beta of 1.29. Portage Biotech has a 12 month low of $2.10 and a 12 month high of $23.01. The company has a 50 day moving average of $4.42 and a two-hundred day moving average of $4.95.

About Portage Biotech

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.